“…From this approach, liposomes can be surface decorated with receptor recognition ligands including antibodies, aptamers, peptides, and integrins to facilitate targeting of specific biomarkers that are identified in disease states. For example, EGFR [38], Folate Receptor [39, 40], and HER2 [41] directed nanotherapies have significantly improved global cancer treatment via cell specific endocytosis of therapeutic cargo. In regards to GBM therapy, a wide array of active recognition ligands have been utilized to date including the peptide sequences IL13 [42, 43], CGKRK [44], Pep1 [45], activatable low molecular weight protamine [46], and chlorotoxin [47], antibodies such as EGFRvIII [48], low density lipoprotein receptor related proteins [49, 50], and the GMT8 aptamer [51].…”